Cannabinoids for the treatment of neuropathic pain: Clinical evidence

Current Opinion in Investigational Drugs

Volumn 9, Issue 1, 2008, Pages 65-75

  Ashton, J C ^a   Milligan, E D ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

9 tetrahydrocannabinol; Ajulemic acid; Analgesia; Cannabidiol; Cannabinoid; Cannabis; CB1 receptor; CB2 receptor; Dronabinol; Levonantradol; Nabilone; Neuropathic pain; Sativex

Indexed keywords

AJULEMIC ACID; ANALGESIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; CANNABIDIOL; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CANNABIS; CODEINE; CYCLOBENZAPRINE; DRONABINOL; GABAPENTIN; GW 2000 202; LEVONANTRADOL; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NABILONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

ATAXIA; BLOOD PRESSURE; CANCER PAIN; CHRONIC PAIN; CLINICAL TRIAL; CONFUSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG ABUSE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EPIDEMIC; FATIGUE; HUMAN; INDUSTRIALIZATION; MENTAL CONCENTRATION; MUCOSAL DISEASE; MYALGIA; NAUSEA; NEUROPATHIC PAIN; PAIN ASSESSMENT; PERIPHERAL NEUROPATHY; POSTHERPETIC NEURALGIA; POSTOPERATIVE PAIN; PSYCHOSIS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; XEROSTOMIA;

ANALGESICS; CANNABINOIDS; HUMANS; PAIN; PERIPHERAL NERVOUS SYSTEM DISEASES;

EID: 38049028807     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (79)

1. Pappagello M: The Neurological Basis of Pain. McGraw-Hill Companies, New York, NY, USA (2005).
2. Merskey HD, Albe-Fessard JJ, Bonica A, Carmon R, Dubner F, Kerr U, Lindblom JM, Mumford PW, Nathan W, Noordenbos CA, Pagni MJ et al: Pain terms: A list with definitions and notes on usage. Recommended by the IASP Subcommittee on taxonomy. Pain (1979) 6(3):249.
3. Smith BH, Torrance N: Epidemiology [of neuropathic pain]. In: Neuropathic Pain. Bennett M (Ed), Oxford University Press, Oxford, UK (2006):17-24.
4. Finnerup NB, Otto M, McQuay HJ, Jensen TS, Sindrup SH: Algorithm for neuropathic pain treatment: An evidence based proposal. Pain (2005) 118(3):289-305. • Meta-analysis of the efficacy of current drug treatments for neuropathic pain.
5. Iversen L: Cannabis and the brain. Brain (2003) 126(6):1252-1270.
6. Elphick MR, Egertová M: The neurobiology and evolution of cannabinoid signalling. Philos Trans R Soc Lond B Biol Sci (2001) 356(1407):381-408.
7. Di Marzo V: A brief history of cannabinoid and endocannabinoid pharmacology as inspired by the work of British scientists. Trends Pharmacol Sci (2006) 27(3):134-140.
8. Pertwee RG: The pharmacology of cannabinoid receptors and their ligands: An overview. Int J Obes (Lond) (2006) 30(Suppl 1):S13-S18. • Excellent, concise review of cannabinoids and their pharmacology.
9. Pertwee RG: Cannabinoid receptors and pain. Prog Neurobiol (2001) 63(5):569-611.
10. 1 receptors in peripheral neuropathic pain.
11. 2 receptors suppresses the maintenance of inflammatory nociception: A comparative analysis. Br J Pharmacol (2007) 150(2):153-163.
12. Burns TL, Ineck JR: Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain. Ann Pharmacother (2006) 40(2):251-260.
13. Huskey A: Cannabinoids in cancer pain management. J Pain Palliat Care Pharmacother (2006) 20(3):43-46.
14. Manzanares J, Julian MD, Carrascosa A: Role of the cannabinoid system in pain control and therapeutic implications for the management of acute and chronic pain episodes. Curr Neuropharmacol (2006) 4(3):239-257.
15. st Edition. Harwood Academic Publishers, Amsterdam, the Netherlands: (1997). • Clinical studies using cannabinoids for the treatment of pain prior to 1997 are reviewed.
16. Report on the medical uses of marijuana. National Institutes of Health, Bethesda, MD, USA (1997).
17. Report of the Council on Scientific Affairs to AMA House of Delegates on Medical Marijuana, in CSA Report. American Medical Association (1997):1-97.
18. Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. Br Med J (2001) 323(7303):13-16. • A systematic review of cannabinoids for the treatment of pain in studies conducted prior to 2001.
19. Moore A, Edwards J, Barden J, McQuay H: Bandolier's Little Book of Pain. An Evidence-Based Guide to Treatments. Oxford University Press, Oxford, UK (2003).
20. Buggy DJ, Toogood L, Maric S, Sharpe P, Lambert DG, Rowbotham DJ: Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain. Pain (2003) 106(1-2):169-172.
21. Greenwald MK, Stitzer ML: Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend (2000) 59(3):261-275.
22. Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R: The analgesic effect of oral δ-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain (2003) 105(1-2):79-88.
23. Holdcroft A, Maze M, Doré C, Tebbs S, Thompson S: A multicenter dose-escalation study of the analgesic and adverse effects of an oral cannabis extract (Cannador) for postoperative pain management. Anesthesiology (2006) 104(5):1040-1046.
24. Roberts JD, Gennings C, Shih M: Synergistic affective analgesic interaction between δ-9-tetrahydrocannabinol and morphine. Eur J Pharmacol (2006) 530(1-2):54-58.
25. Ware MA, Gamsa A, Persson J, Fitzcharles MA: Cannabis for chronic pain: Case series and implications for clinicians. Pain Res Manag (2002) 7(2):95-99.
26. Ware MA, Doyle CR, Woods R, Lynch ME, Clark AJ: Cannabis use for chronic non-cancer pain: Results of a prospective survey. Pain (2003) 102(1-2):211-216.
27. Ware MA, Adams H, Guy GW: The medicinal use of cannabis in the UK: Results of a nationwide survey. Int J Clin Pract (2005) 59(3):291-295.
28. Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A: Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage (2005) 29(4):358-367.
29. Lynch ME, Young J, Clark AJ: A case series of patients using medicinal marihuana for management of chronic pain under the Canadian Marihuana Medical Access Regulations. J Pain Symptom Manage (2006) 32(5):497- 501.
30. Adams IB, Martin BR: Cannabis: Pharmacology and toxicology in animals and humans. Addiction (1996) 91(11):1585-1614.
31. Clark AJ, Ware MA, Yazer E, Murray TJ, Lynch ME: Patterns of cannabis use among patients with multiple sclerosis. Neurology (2004) 62(11):2098-2100.
32. Chong MS, Wolff K, Wise K, Tanton C, Winstock A, Silber E: Cannabis use in patients with multiple sclerosis. Mult Scler (2006) 12(5):646-651.
33. 9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain. Presse Med (2002) 31(39 Pt 1):1840-1845.
34. Attal N, Brasseur L, Guirimand D, Clermond-Gnamien S, Atlami S, Bouhassira D: Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain (2004) 8(2):173-177.
35. Wade DT, Makela P, Robson P, House H, Bateman C: Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler (2004) 10(4):434-441. • Medium/large trial that assessed pain in patients with MS treated with Sativex and did not find a statistically significant effect compared with placebo. Interpretation of this result is limited by the absence of regulation of the placebo group's access to rescue analgesia.
36. Iskedjian M, Bereza B, Gordon A, Piwko C, Einarson TR: Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin (2007) 23(1):17-24. •• The only attempt at a meta-analysis in the area of cannabinoids and neuropathic pain is reported. The number of trials included is small due to heterogeneity in the inclusion criteria and outcome measures across clinical studies, but the results nonetheless suggest that cannabinoids are clinically relevant tools for the treatment of neuropathic pain.
37. Holdcroft A, Smith M, Jacklin A, Hodgson H, Smith B, Newton M, Evans F: Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia (1997) 52(5):483-486.
38. Wade DT, Robson P, House H, Makela P, Aram J: A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil (2003) 17(1):21-29. • A trial that studied the effects of cannabinoids in treating a range of chronic pain syndromes.
39. Notcutt W, Price M, Miller R, Newport S, Phillips C, Simmons S, Sansom C: Initial experiences with medicinal extracts of cannabis for chronic pain: Results from 34 'N of 1' studies. Anaesthesia (2004) 59(5):440-452.
40. Berman JS, Symonds C, Birch R: Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain (2004) 112(3):299-306. • A clinical study with relatively low degree of heterogeneity in the outcome measure compared with other studies on cannabinoid analgesia.
41. Blake DR, Robson P, Ho M, Jubb RW, McCabe CS: Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology (2006) 45(1):50-52.
42. Pinsger M, Schimetta W, Volc D, Hiermann E, Riederer F, Pölz W: Benefits of an add-on treatment with the synthetic cannabinomimetic nabilone on patients with chronic pain - A randomized controlled trial. Wien Klin Wochenschr (2006) 118(11-12):327-335. • A rigorous trial that provides a rationale for the use of an already-in-use cannabinoid for the treatment of pain in MS.
43. Berlach DM, Shir Y, Ware MA: Experience with the synthetic cannabinoid nabilone in chronic noncancer pain. Pain Med (2006) 7(1):25-29.
44. Karst M, Salim K, Burstein S, Conrad I, Hoy L, Schneider U: Analgesic effect of the synthetic cannabinoid CT-3 on chronic neuropathic pain: A randomized controlled trial. J Am Med Assoc (2003) 290(13):1757-1762. • The analgesic effects of ajulemic acid in humans with neuropathic pain were demonstrated in this trial.
45. Salim K, Schneider U, Burstein S, Hoy L, Karst M: Pain measurements and side effect profile of the novel cannabinoid ajulemic acid. Neuropharmacology (2005) 48(8):1164-1171.
46. Svendsen KB, Jensen TS, Bach FW: Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. Br Med J (2004) 329(7460):253. •• A rigorous study into the use of a relatively commonly used cannabinoid that provides a rationale for its use in controlling central pain in patients with MS.
47. Wissel J, Haydn T, Müller J, Brenneis C, Berger T, Poewe W, Schelosky LD: Low dose treatment with the synthetic cannabinoid nabilone significantly reduces spasticity-related pain: A double-blind placebo-controlled cross-over trial. J Neurol (2006) 253(10):1337-1341.
48. Rog DJ, Nurmikko TJ, Friede T, Young CA: Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology (2005) 65(6):812-819. •• This trial specifically assessed the effects of Sativex for the control of pain in MS.
49. Wade DT, Makela PM, House H, Bateman C, Robson P: Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult Scler (2006) 12(5):639-645. •• Long-term open-label data on the efficacy and safety of cannabinoids for the treatment of MS and related pain are reported.
50. Zajicek J, Fox P, Sanders H, Wright D, Vickery J, Nunn A, Thompson A: Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): Multicentre randomised placebo-controlled trial. Lancet (2003) 362(9395):1517-1526. •• A large placebo-controlled trial which included pain as one outcome measure. Interpretation of results was limited by the presentation of data as categorical ratings rather than quantitative ratings on an 11- or 100-point scale.
51. Zajicek JP, Sanders HP, Wright DE, Vickery PJ, Ingram WM, Reilly SM, Nunn AJ, Teare LJ, Fox PJ, Thompson AJ: Cannabinoids in multiple sclerosis (CAMS) study: Safety and efficacy data for 12 months follow up. J Neurol Neurosurg Psychiatry (2005) 76(12):1664-1669. •• Long-term, placebo-controlled trial data on cannabinoid efficacy and safety in the treatment of MS and related pain are reported.
52. Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Kelly ME, Rowbotham MC, Petersen L: Cannabis in painful HIV-associated sensory neuropathy: A randomized placebo-controlled trial. Neurology (2007) 68(7):515-521. • A rare clinical trial that tested smoked cannabis for its effect on one type of neuropathic pain.
53. Ashton JC: Cannabinoids for the treatment of inflammation. Curr Opin Investig Drugs (2007) 8(5):373-384.
54. Vaney C, Heinzel-Gutenbrunner M, Jobin P, Tschopp F, Gattlen B, Hagen U, Schnelle M, Reif M: Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: A randomized, double-blind, placebo-controlled, crossover study. Mult Scler (2004) 10(4):417-424.
55. Cardenas DD, Jensen MP: Treatments for chronic pain in persons with spinal cord injury: A survey study. J Spinal Cord Med (2006) 29(2):109-117.
56. Consroe P, Tillery W, Rein J, Musty RE: Reported marijuana effects in patients with spinal cord injury. In: Symposium on Cannabinoids. International Cannabinoid Research Society, Burlington, Vermont, USA (1998):64.
57. Ranganathan M, D'Souza DC: The acute effects of cannabinoids on memory in humans: A review. Psychopharmacology (2006) 188(4):425- 444.
58. Jain AK, Ryan JR, McMahon FG, Smith G: Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol (1981) 21:320S-326S. • This study demonstrated that potent cannabinoids can reduce acute pain, but their effectiveness is limited by drug psychoactivity.
59. Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G: Cannabis use and risk of psychotic or affective mental health outcomes: A systematic review. Lancet (2007) 370(9584):319- 328.
60. Lichtman AH, Martin BR: Cannabinoid tolerance and dependence. Handb Exp Pharmacol (2005) 168:691-717. • A good discussion of tolerance to cannabinoids is provided.
61. Jones RT, Benowitz NL, Herning RI: Clinical relevance of cannabis tolerance and dependence. J Clin Pharmacol (1981) 21(8-9 Suppl):143S-152S.
62. Tappe-Theodor A, Agarwal N, Katona I, Rubino T, Martini L, Swiercz J, Mackie K, Monyer H, Parolaro D, Whistler J, Kuner T, Kuner R: A molecular basis of analgesic tolerance to cannabinoids. J Neurosci (2007) 27(15):4165-4177.
63. Ware MA, Gamsa A, Persson J, Fitzcharles MA: Cannabis for chronic pain: Case series and implications for clinicians. Pain Res Manag (2002) 7(2):95-99.
64. Babor TF, Mendelson JH, Greenberg I, Kuehnle JC: Marijuana consumption and tolerance to physiological and subjective effects. Arch Gen Psychiatry (1975) 32(12):1548-1552.
65. Iversen LL: The Science of Marijuana. Oxford University Press, Oxford, UK (2000).
66. Burstein SH, Karst M, Schneider U, Zurier RB: Ajulemic acid: A novel cannabinoid produces analgesia without a "high". Life Sci (2004) 75(12):1513-1522.
67. Karst M: Comments on "cannabimimetic properties of ajulemic acid". J Pharmacol Exp Ther (2007) 322(1):420-421.
68. Vann RE, Cook CD, Martin BR, Wiley JL: Cannabimimetic properties of ajulemic acid. J Pharmacol Exp Ther (2007) 320(2):678-686. • This paper challenges the idea that ajulemic acid is not psychoactive.
69. 2 agonist reverses post-operative hyperalgesia in rats. This is a promising direction for cannabinoid analgesia.
70. 2-selective drug to reduce chronic and inflammatory pain.
71. Costa B, Siniscalco D, Trovato AE, Comelli F, Sotgiu ML, Colleoni M, Maione S, Rossi F, Giagnoni G: AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol (2006) 148(7):1022- 1032.
72. Maione S, De Petrocellis L, de Novellis V, Moriello AS, Petrosino S, Palazzo E, Rossi FS, Woodward DF, Di Marzo V: Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors. Br J Pharmacol (2007) 150(6):766-781.
73. Minutolo F, Cascio MG, Carboni I, Bisogno T, Prota G, Bertini S, Digiacomo M, Bifulco M, Di Marzo V, Macchia M: Metabolically labile cannabinoid esters: A 'soft drug' approach for the development of cannabinoid-based therapeutic drugs. Bioorg Lett Chem Lett (2007) 17(17):4878-4881.
74. Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR: Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci (2003) 23(3):1026-1040.
75. 2 receptor-mediated antihyperalgesia: Possible direct involvement of neural mechanisms. Eur J Neurosci (2006) 23(6):1530-1538.
76. 2 receptor expression in the rat spinal cord of neuropathic but not inflammatory chronic pain models. Eur J Neurosci (2003) 17(12):2750-2754.
77. 2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 119(3):747-757.
78. 2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 92(6):3562-3574.
79. Noyes R Jr, Brunk SF, Baram DA, Canter A: Analgesic effect of δ-9-tetrahydrocannabinol. J Clin Pharmacol (1975) 15(2-3):139-143.